- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- AZN
- Stock Information
- Founded
- NVS 1895
- AZN 1992
- Country
- NVS Switzerland
- AZN United Kingdom
- Employees
- NVS N/A
- AZN N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- AZN Health Care
- Exchange
- NVS Nasdaq
- AZN Nasdaq
- Market Cap
- NVS 248.3B
- AZN 252.9B
- IPO Year
- NVS 1991
- AZN 1993
- Fundamental
- Price
- NVS $131.88
- AZN $85.38
- Analyst Decision
- NVS Sell
- AZN Strong Buy
- Analyst Count
- NVS 4
- AZN 1
- Target Price
- NVS $119.00
- AZN N/A
- AVG Volume (30 Days)
- NVS 1.4M
- AZN 5.7M
- Earning Date
- NVS 10-28-2025
- AZN 11-11-2025
- Dividend Yield
- NVS 1.98%
- AZN 1.80%
- EPS Growth
- NVS N/A
- AZN 28.86
- EPS
- NVS 6.85
- AZN 5.31
- Revenue
- NVS $55,186,000,000.00
- AZN $56,501,000,000.00
- Revenue This Year
- NVS $9.06
- AZN $10.87
- Revenue Next Year
- NVS $2.54
- AZN $6.12
- P/E Ratio
- NVS $19.13
- AZN $16.02
- Revenue Growth
- NVS 12.95
- AZN 15.00
- 52 Week Low
- NVS $96.06
- AZN $61.24
- 52 Week High
- NVS $133.55
- AZN $86.57
- Technical
- Relative Strength Index (RSI)
- NVS 67.52
- AZN 67.92
- Support Level
- NVS $131.32
- AZN $85.16
- Resistance Level
- NVS $133.16
- AZN $86.48
- Average True Range (ATR)
- NVS 1.60
- AZN 1.47
- MACD
- NVS 0.63
- AZN 0.95
- Stochastic Oscillator
- NVS 87.26
- AZN 91.55
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.